Welcome to our dedicated page for 22Nd Century news (Ticker: XXII), a resource for investors and traders seeking the latest updates and insights on 22Nd Century stock.
News for 22nd Century Group, Inc. (Nasdaq: XXII) centers on its role in tobacco harm reduction, regulatory developments, capital structure actions and the commercialization of its VLN® reduced nicotine cigarette platform. Company announcements frequently highlight progress in expanding VLN® and partner VLN® distribution across additional U.S. states and retail chains, including launches with major convenience store operators and authorizations in a large majority of states.
Investors following XXII news will see updates on VLN® regulatory milestones, such as the original FDA Modified Risk Tobacco Product authorization, the filing of the VLN® MRTP renewal application, and the company’s public support for the FDA’s proposed Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products. Releases also discuss clinical research findings related to very low nicotine content cigarettes, including reductions in daily cigarette consumption and increased quit attempts among smokers using 95% reduced nicotine VLN® products.
Another recurring theme in 22nd Century’s news is financial and corporate developments. The company reports on balance sheet changes such as repayment and termination of senior secured debt, settlement of insurance claims related to prior facility incidents, and the use of non-dilutive cash proceeds as growth capital. News items also cover equity and preferred stock financings, at-the-market offering arrangements, and proposals for reverse stock splits and other shareholder approvals under Nasdaq Listing Rules.
In addition, XXII news includes corporate governance and investor relations events, such as participation in investor conferences, quarterly earnings webcasts, and shareholder letters reviewing strategic progress. For readers tracking the intersection of tobacco regulation, reduced nicotine technology and public company capital markets activity, the XXII news feed provides ongoing context on how 22nd Century is executing its harm reduction-focused strategy.
22nd Century Group, Inc. (NYSE American: XXII) announced participation in the FDA’s Tobacco and Nicotine Products Regulation Conference, highlighting advancements in reduced nicotine technology.
Mitchell R. Zeller from the FDA will discuss the Comprehensive Plan on October 21, 2020, while 22nd Century's regulatory VP, John Pritchard, will speak on nicotine and harm reduction on October 22, 2020. Pritchard emphasized that limiting nicotine could help 5 million adult smokers quit within a year and save over 8 million lives by century's end. The company aims to support the FDA's efforts in reducing nicotine standards across the tobacco industry.
22nd Century Group has been awarded a new U.S. patent (No. 10,669,552) allowing precise genetic control over nicotine levels in various tobacco plant varieties. This technology can facilitate the introduction of very low nicotine traits into multiple tobacco types, supporting the FDA’s plan to limit nicotine content in cigarettes. The company is also preparing to launch its VLN® cigarettes, which contain 95% less nicotine than traditional cigarettes, pending FDA approval. This innovation aligns with their mission to reduce smoking harm and disrupt the $100 billion U.S. tobacco market.
22nd Century Group (NYSE American: XXII) reported an update from CEO James A. Mish, emphasizing the urgency of their Modified Risk Tobacco Product (MRTP) application with the FDA for their VLN® reduced nicotine cigarettes. The company is optimistic about receiving authorization, which could significantly boost market value by capturing just 0.25% of the U.S. tobacco market, potentially leading to a 5-10x increase in market capitalization. Additionally, the firm aims to advance its hemp/cannabis technology while holding over 200 patents.
22nd Century Group (NYSE American: XXII) has appointed Dr. Michael Koganov to its Board of Directors, enhancing the company's leadership in plant biotechnology. Dr. Koganov will chair the Scientific and Technical Advisory Committee and join the Finance Committee. He brings significant expertise in developing natural plant-based technologies, with a history of success in the life sciences sector. His appointment is expected to strengthen 22nd Century's strategic initiatives and R&D efforts, especially as the company focuses on innovative solutions in the tobacco and cannabis markets.
22nd Century Group (NYSE American: XXII) will present at the LD Micro 500 Virtual Conference on September 3, 2020, at 4:20 p.m. ET. The executive team will be available for one-on-one meetings with investors on September 3 and 4. A live webcast will be accessible on the company’s Investors webpage, with archived replays available post-event. The company specializes in plant-based biotechnology and has innovative products, such as reduced nicotine tobacco. Their expertise extends to developing unique varieties in hemp and cannabis, holding over 200 patents.
22nd Century Group (NYSE American: XXII) announced a live audio webcast scheduled for August 6, 2020, at 8:00 a.m. ET to discuss its second quarter 2020 results. A press release revealing the results will be issued at 7:00 a.m. ET on the same day. Key executives, including CEO James A. Mish, COO Michael Zercher, and CFO John Franzino, will present during the event. Investors can access the webcast through the company's Investor Relations website, and an archived replay will be available afterward.
22nd Century Group has appointed James A. Mish as the new CEO effective June 22, 2020, and John Franzino as the CFO immediately. Mish brings significant executive leadership experience in pharmaceuticals and cannabinoids, previously leading Noramco and its spinoff, Purisys. The company anticipates growth through its reduced nicotine cigarettes and new cannabinoid products. Franzino, with a background in finance for tobacco and alcoholic beverages, is expected to navigate the company through its growth phase. Former CFO Andrea Jentsch resigned for personal reasons.
Summary not available.